Chemours Co (CC) · Aug 4, 2026 · Company update

Revenue missed consensus as EBITDA hit the high end; outlook stayed put.

Revenue missed consensus as EBITDA hit the high end; outlook stayed put.

The headline quarter was mixed versus the market’s setup. Adjusted EPS of $0.42 essentially matched the published consensus of roughly $0.42–$0.43, but sales of $1.591 billion were about 4% below the published $1.66 billion expectation. Operating profit was more resilient than revenue: adjusted EBITDA reached $247 million, near the top of the company’s prior $220–$250 million Q2 range. The result is not a clean beat: pricing protected earnings, while demand/volume came in softer. (Total Chemours — Financial Highlights)

MetricQ2 2026 actualComparisonRead-through
Net sales$1.591B$1.615B year ago; ~$1.66B published consensus1% lower year over year; missed expectations
Adjusted EPS$0.42$0.61 year ago; ~$0.42–$0.43 published consensusRoughly in line, but down 31% year over year
Adjusted EBITDA$247M$260M year ago; prior company guide $220M–$250MNear the high end of guidance, but still down 5%
Free cash flow$114M$50M year agoMaterial improvement in quarterly cash generation
Net leverage4.4x4.6x comparative trailing-period ratioMoving down, but remains elevated
Full-year adjusted EBITDA outlook$775M–$825MUnchangedNo upgrade despite a high-end Q2 EBITDA result

Pricing, not underlying volume, did the work. Companywide price rose 2%, but volume fell 4%. TSS held its EBITDA margin at a strong 36%, yet Opteon refrigerant sales fell 10% year over year after an unusually strong 2025 channel-fill period. TT pricing improved, but its volume also declined 2% and margin stayed only 7%. This matters because the sales miss was broad demand/mix pressure rather than a one-off accounting issue. (Quarterly Change in Net Sales; Segment Financial and Operating Data)

The better cash result is real progress, but it does not remove the balance-sheet overhang. Free cash flow more than doubled year over year to $114 million, and the company used land-sale proceeds plus organic cash to repay part of its euro term loan. Net debt stood at $3.243 billion and net leverage at 4.4x. But stockholders’ equity turned to negative $49 million from positive $250 million at year-end, while environmental-remediation liabilities rose to $795 million from $618 million. (Liquidity and Capital Allocation; Consolidated Balance Sheets; Free Cash Flow Reconciliation)

The GAAP loss shows the legacy-liability burden is still substantial. The reported loss was $274 million, even after a $266 million gain on asset sales, because the adjusted-results bridge excludes $225 million of litigation-related charges and $144 million of environmental charges in the quarter. Those exclusions help isolate operating performance, but they do not make the obligations disappear; they remain central to the financial-risk picture. (Consolidated Statements of Operations; GAAP Net Loss to Adjusted EBITDA Reconciliation)

Keeping full-year guidance unchanged limits the upside message. Management retained its $775–$825 million adjusted EBITDA and 1%–5% sales-growth outlook, while guiding Q3 EBITDA down to $175–$205 million as TSS faces weaker seasonal demand and elevated Opteon channel inventories. TT pricing and a more normalized APM plant are offsets, but the filing does not raise the full-year earnings bar after the near-top-end Q2 EBITDA result. (Third Quarter 2026 Outlook; Full Year 2026 Outlook)

Original filing on SEC EDGAR

More Chemours Co news

Revenue missed consensus as EBITDA hit the high end; outlook stayed put. | CC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.